Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2- Metastatic Breast Cancer.

Clinicoecon Outcomes Res · 2025 · PMC11955739 · PMID 40165979

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

borderline significantP = 0.05actually significant

Compared with palbociclib, incremental initial period costs were higher (borderline significant) for abemaciclib (incremental cost: $5,556 [95% CI: -$71 to $11,183], P = 0.05) and not statistically different for ribociclib (incremental cost: $1,769 [95% CI: -$2,602 to $6,139], P = 0.43).

also in 6,883 other papers

a strong trendno p-value reported

In addition, there was a strong trend for higher medical costs during the initial 3-month treatment period with abemaciclib.

also in 3,343 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.